Jørgensen 2002.

Methods	RCT, double‐blinded, venography.
Participants	Patients undergoing curative surgery for abdominal or pelvic cancer.
Interventions	LMWH (tinzaparin 3500 IU, total treatment period of 28 days) or placebo.
Outcomes	LMWH 58 Placebo 50
Notes	Unpublished data. Presented as an abstract.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated allocation.
Allocation concealment (selection bias)	Unclear risk	Not described in abstract.
Blinding (performance bias and detection bias) All outcomes	Low risk	Placebo‐controlled double‐blind study. Patients, healthcare providers, data collectors, outcome assessors and data analysts were blinded.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described in abstract.
Incomplete outcome data (attrition bias) All outcomes	High risk	Study terminated prematurely due to lack of funding and high attrition rate (rate not reported).
Selective reporting (reporting bias)	Unclear risk	Intention‐to‐treat analysis of patients reaching an evaluable VTE end point (venogram or objection verification of symptomatic VTE). Adequate definitions of VTE and bleeding complications were described.
Other bias	High risk	Premature termination of trial. Full details of study unclear because Abstract only. Bilateral venography performed on day 28 to 35.